Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.diagmicrobio.2021.115324 http://scihub22266oqcxt.onion/10.1016/j.diagmicrobio.2021.115324 33529938!7826079!33529938     free     free     free Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Diagn+Microbiol+Infect+Dis 2021 ; 100 (1): 115324 Nephropedia Template TP {{tp|p=33529938|t=2021. Automated molecular testing of saliva for SARS-CoV-2 detection |pdf=|usr=}}{{33529938}} gab.com Text Automated molecular testing of saliva for SARS-CoV-2 detection JO: Diagn Microbiol Infect Dis http://www.kidney.de/pget.php?&tw=1&pmid=33529938 #FOAvip With surging global demand for SARS-CoV-2 testing capacity, laboratories seek automated, high-throughput molecular solutions, particularly for specimens not requiring specialized collection devices or viral transport media. Saliva specimens submitted from patients under investigation for COVID-19 from March to July 2020 were processed in the laboratory with sterile phosphate-buffered saline in a 1:2 dilution and tested using manual extraction and a commercial assay for detection of the SARS-CoV-2 E gene (LightMix(R)) in comparison to the Roche cobas(R) SARS-CoV-2 Test on the cobas(R) 6800 instrument. 34.4% (22/64) of saliva samples were positive for SARS-CoV-2. Positive and negative concordance between the LightMix(R) and cobas(R) assays were 100%. The overall invalid rate for saliva on the cobas(R) 6800 (1/128, 0.78%) was similar to the baseline invalid rate observed for nasopharyngeal swabs/viral transport media. Saliva is a feasible specimen type for SARS-CoV-2 testing on the cobas(R) 6800 platform, with potential to improve turnaround time and enhance testing capacity. Twit Text FOAVip Automated molecular testing of saliva for SARS-CoV-2 detection ????Diagn Microbiol Infect Dis http://www.kidney.de/pget.php?&tw=1&pmid=33529938 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33529938 #FOAvip English Wikipedia <ref>{{Cite pmid|33529938}}</ref> Automated molecular testing of saliva for SARS-CoV-2 detection #MMPMID33529938 Matic N; Lawson T; Ritchie G; Stefanovic A; Leung V; Champagne S; Romney MG; Lowe CF Diagn Microbiol Infect Dis 2021[May]; 100 (1): 115324 PMID33529938show ga With surging global demand for SARS-CoV-2 testing capacity, laboratories seek automated, high-throughput molecular solutions, particularly for specimens not requiring specialized collection devices or viral transport media. Saliva specimens submitted from patients under investigation for COVID-19 from March to July 2020 were processed in the laboratory with sterile phosphate-buffered saline in a 1:2 dilution and tested using manual extraction and a commercial assay for detection of the SARS-CoV-2 E gene (LightMix(R)) in comparison to the Roche cobas(R) SARS-CoV-2 Test on the cobas(R) 6800 instrument. 34.4% (22/64) of saliva samples were positive for SARS-CoV-2. Positive and negative concordance between the LightMix(R) and cobas(R) assays were 100%. The overall invalid rate for saliva on the cobas(R) 6800 (1/128, 0.78%) was similar to the baseline invalid rate observed for nasopharyngeal swabs/viral transport media. Saliva is a feasible specimen type for SARS-CoV-2 testing on the cobas(R) 6800 platform, with potential to improve turnaround time and enhance testing capacity. |Automation, Laboratory[MESH] |COVID-19 Testing/*methods[MESH] |Humans[MESH] |Molecular Diagnostic Techniques[MESH] |Saliva/*virology[MESH]Automated molecular testing of saliva for SARS-CoV-2 detection (epmc).pdf DeepDyve Pubget Overpricing